Real-World Durability of Effectiveness Through 24 Months of Anti-IL-17A Biologics and Other Approved Biologics in Treating Patients With Moderate-to-Severe Psoriasis in the PSoHO
Por:
Tjioe, M, Costanzo, A, Carrascosa, JM, Bovenschen, HJ, Maul, JT, de Hoog, N, Martimianaki, G, Lampropoulou, A, Mckenzie, R, Pinter, A and Fotiou, K
Publicada:
1 abr 2025
Resumen:
Filiaciones:
Tjioe, M:
Bravis Hosp, DermaTeam Res, Roosendaal, Netherlands
Costanzo, A:
Univ Milan, Dept Human Anat, Milan, Italy
:
Univ Autonoma Barcelona, Hosp Universitari Germans Trias i Pujol, Cardiol Dept, Badalona, Barcelona, Spain
Bovenschen, HJ:
Maxima Med Ctr, Veldhoven, Netherlands
Maul, JT:
Univ Hosp Zurich, Zurich, Switzerland
de Hoog, N:
Eli Lilly & Co, Indianapolis, IN USA
Martimianaki, G:
Eli Lilly & Co, Indianapolis, IN USA
Lampropoulou, A:
Eli Lilly & Co, Indianapolis, IN USA
Mckenzie, R:
Eli Lilly & Co, Indianapolis, IN USA
Pinter, A:
Univ Hosp Frankfurt, Frankfurt, Germany
Fotiou, K:
Lilly Deutschland GmbH, Bad Homburg, Germany
|